CN107090040A - Dac hyp组合物和方法 - Google Patents

Dac hyp组合物和方法 Download PDF

Info

Publication number
CN107090040A
CN107090040A CN201710204584.8A CN201710204584A CN107090040A CN 107090040 A CN107090040 A CN 107090040A CN 201710204584 A CN201710204584 A CN 201710204584A CN 107090040 A CN107090040 A CN 107090040A
Authority
CN
China
Prior art keywords
dac
daclizumab
dac hyp
cell
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710204584.8A
Other languages
English (en)
Chinese (zh)
Inventor
T.哈特曼
P.W.索尔
J.E.伯基
M.C.韦森
P.Y.黄
T.J.罗宾逊
B.帕特里奇
J.Y.索
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
AbbVie Biotherapeutics Inc
Original Assignee
Abbott Biotech Ltd Bermuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Biotech Ltd Bermuda filed Critical Abbott Biotech Ltd Bermuda
Publication of CN107090040A publication Critical patent/CN107090040A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201710204584.8A 2011-05-27 2012-05-25 Dac hyp组合物和方法 Pending CN107090040A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490998P 2011-05-27 2011-05-27
US61/490,998 2011-05-27
CN2012102472614A CN102796705A (zh) 2011-05-27 2012-05-25 Dac hyp组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2012102472614A Division CN102796705A (zh) 2011-05-27 2012-05-25 Dac hyp组合物和方法

Publications (1)

Publication Number Publication Date
CN107090040A true CN107090040A (zh) 2017-08-25

Family

ID=46177353

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710204584.8A Pending CN107090040A (zh) 2011-05-27 2012-05-25 Dac hyp组合物和方法
CN2012102472614A Pending CN102796705A (zh) 2011-05-27 2012-05-25 Dac hyp组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012102472614A Pending CN102796705A (zh) 2011-05-27 2012-05-25 Dac hyp组合物和方法

Country Status (10)

Country Link
US (7) US20120301429A1 (enExample)
EP (1) EP2527429A3 (enExample)
JP (4) JP6055615B2 (enExample)
CN (2) CN107090040A (enExample)
AU (4) AU2012203095B2 (enExample)
BR (1) BR102012012673A8 (enExample)
CA (1) CA2777978A1 (enExample)
MX (1) MX339533B (enExample)
RU (2) RU2661764C2 (enExample)
SG (1) SG185920A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107090040A (zh) * 2011-05-27 2017-08-25 艾伯维生物技术有限公司 Dac hyp组合物和方法
US9809652B2 (en) 2011-08-08 2017-11-07 Abbvie Biotherapeutics Inc. Methods of treating progressive forms of multiple sclerosis comprising subcutaneously administering daclizumab
CA2857298A1 (en) * 2011-11-30 2013-06-06 Abbvie Biotherapeutics Inc. Vectors and host cells comprising a modified sv40 promoter for protein expression
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
EP3041857B1 (en) 2013-09-04 2019-05-08 EMD Millipore Corporation Protein a chromatography
GB201503578D0 (en) * 2015-03-03 2015-04-15 Ge Healthcare Bio Sciences Ab Sanitization method for affinity chromatography matrices
WO2016154290A1 (en) * 2015-03-23 2016-09-29 Alexion Pharmaceuticals, Inc. Virus filtration
CA2938333A1 (en) * 2015-08-12 2017-02-12 Pfizer Inc. Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation
EP3408397B1 (en) 2016-01-27 2020-07-15 Just-Evotec Biologics, Inc. Hybrid promoter and uses thereof
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
WO2018027195A1 (en) 2016-08-05 2018-02-08 Abbvie Biotherapeutics Inc. Compositions containing reduced amounts of daclizumab acidic isoforms and methods for preparing the same
CN110267721B (zh) * 2017-01-30 2022-03-01 瑞泽恩制药公司 用于降低色谱中生物负载的组合物和方法
AU2018392697B2 (en) * 2017-12-21 2025-08-14 Genzyme Corporation Methods for enhanced removal of impurities during protein a chromatography
KR20210148349A (ko) * 2019-04-17 2021-12-07 브리스톨-마이어스 스큅 컴퍼니 크로마토그래피 수지의 재생 방법
KR102731889B1 (ko) * 2019-07-18 2024-11-19 에이비온 주식회사 2당화된 인터페론-베타 단백질의 정제 방법
MX2022001166A (es) * 2019-08-01 2022-02-23 Regeneron Pharma Metodo para inactivacion viral.
JP2022548197A (ja) 2019-12-06 2022-11-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｖｅｇｆタンパク質組成物及びその製造方法
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
JP7631742B2 (ja) * 2020-11-10 2025-02-19 東ソー株式会社 ペプチド性リガンド固定化カラムの洗浄方法
CN114181300A (zh) * 2021-12-20 2022-03-15 方坦思(上海)生物医药有限公司 一种高纯度单克隆抗体的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276799A1 (en) * 2002-10-15 2005-12-15 Hinton Paul R Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1430566A (en) * 1974-11-15 1976-03-31 Nestel Sa Isolation of proteins
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
RU2318537C2 (ru) * 2001-04-06 2008-03-10 Юниверсити Оф Бристоль Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам
JP2005325133A (ja) * 2001-10-15 2005-11-24 Kirin Brewery Co Ltd 抗ｈｌａ−ｄｒ抗体の利用
US20040002135A1 (en) * 2002-03-28 2004-01-01 Sauer Paul W. Adapted NS0 cell lines with the ability to grow under glutamine-free conditions
JPWO2004087761A1 (ja) * 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
US20100173323A1 (en) * 2006-06-09 2010-07-08 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
US20100234577A1 (en) * 2006-06-14 2010-09-16 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
WO2008004931A1 (en) * 2006-07-06 2008-01-10 Ge Healthcare Bio-Sciences Ab Disinfection/sanitation method where the material is treated with a solution comprising benzyl alcohol and c2-3 alcohol
WO2009114641A1 (en) * 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
US20100055098A1 (en) * 2008-08-28 2010-03-04 Facet Biotech Corporation Method for treating multiple sclerosis patients with anti-il2r antibodies
AU2010254215A1 (en) * 2009-05-26 2011-12-01 Momenta Pharmaceuticals, Inc. Production of glycoproteins
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
CN102574911B (zh) * 2009-08-07 2017-06-06 Emd密理博公司 从样品的一或多种杂质中纯化靶蛋白的方法
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
IL300733B1 (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
CN107090040A (zh) 2011-05-27 2017-08-25 艾伯维生物技术有限公司 Dac hyp组合物和方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276799A1 (en) * 2002-10-15 2005-12-15 Hinton Paul R Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KATSUHIRO MORI: "Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies", 《CYTOTECHNOLOGY》 *
晁阳: "治疗性抗体糖基化研究进展及应用", 《山东化工》 *
赵亮等: "表达抗-CD25 单克隆抗体的GS-NS0 骨髓瘤细胞无血清培养及代谢特性", 《生物工程学报》 *

Also Published As

Publication number Publication date
AU2016202873B2 (en) 2018-02-22
AU2012203095B2 (en) 2016-02-04
US20150203583A1 (en) 2015-07-23
AU2016202873A1 (en) 2016-05-26
RU2661764C2 (ru) 2018-07-19
RU2018119112A (ru) 2018-11-07
AU2020202298A1 (en) 2020-04-23
US20180127506A1 (en) 2018-05-10
EP2527429A3 (en) 2013-10-30
JP2016210796A (ja) 2016-12-15
MX339533B (es) 2016-05-30
US20120301429A1 (en) 2012-11-29
SG185920A1 (en) 2012-12-28
US9340619B2 (en) 2016-05-17
US9260528B2 (en) 2016-02-16
RU2012121876A (ru) 2013-11-27
BR102012012673A2 (pt) 2015-11-17
US20200157230A1 (en) 2020-05-21
US20150197573A1 (en) 2015-07-16
JP2018134091A (ja) 2018-08-30
EP2527429A2 (en) 2012-11-28
JP2020078348A (ja) 2020-05-28
JP2012244993A (ja) 2012-12-13
AU2012203095A1 (en) 2012-12-13
CN102796705A (zh) 2012-11-28
MX2012006115A (es) 2012-12-04
AU2018200654A1 (en) 2018-02-15
CA2777978A1 (en) 2012-11-27
US20170247461A1 (en) 2017-08-31
JP6055615B2 (ja) 2016-12-27
BR102012012673A8 (pt) 2021-02-17
US9676860B2 (en) 2017-06-13
US20150274832A1 (en) 2015-10-01
US9815903B2 (en) 2017-11-14

Similar Documents

Publication Publication Date Title
CN107090040A (zh) Dac hyp组合物和方法
US12492377B2 (en) Modified NK-92 haNK003 cells for the clinic
KR101828828B1 (ko) 항-히알루로난 제제 치료를 위한 동반 진단 및 이의 사용 방법
CA2648675C (en) Mature dendritic cell compositions and methods for culturing same
US20220017594A1 (en) Il-2 dependent nk-92 cells with stable fc receptor expression
JP2024037917A (ja) 組換えｔ細胞受容体遺伝子を用いて細胞ベースの治療薬を製造するための技法
CN106008722B (zh) 一种重组β-hNGF-Fc融合蛋白、制备方法及用途
US20020141990A1 (en) Anti-RSV human monoclonal antibodies
CN106749681A (zh) 靶向人FRα的基因工程化NKT细胞及其制备方法和应用
WO1998019704A1 (en) Human monoclonal antibodies
CN107058390A (zh) 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用
CN114874332B (zh) 经修饰的rnf112作为治疗als药物的应用
DE602004011502T2 (de) Rekombinantes fel d 1 allergen
CN111826397A (zh) 生产重组目标蛋白的方法、过表达载体以及病毒悬液
WO2014115087A2 (en) A method for the preparation of recombinant human prothrombin and fibrinogen
WO2025176694A1 (en) Populations of small extracellular vesicles for use in the treatment or prevention of ischemia
WO2018229767A1 (en) Methods for improving cell protein production yields
HK1178205A (en) Dac hyp compositions and methods

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170825

WD01 Invention patent application deemed withdrawn after publication